Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Update on Therapeutic Advances in T-Cell Lymphoma

Access Activity

Overview / Abstract:

Join Steven M. Horwitz, MD, Member and Attending Physician at Memorial Sloan Kettering Cancer Center, as he discusses guideline recommendations for differential diagnosis of TCL, novel treatment strategies, and best practices for managing side effects in this case-based CME/NCPD activity!


Each year, 74,240 new cases of non-Hodgkin lymphoma are diagnosed and 19,940 people die of the disease (ACS, 2020). Among these cases, 12% to 15% are classified as peripheral T-cell lymphomas (PTCL), which comprise more than 10 different T-cell lymphomas (Zain, 2020). The diagnosis of PTCL is challenging, and 26% are categorized as PTCL, not otherwise specified (PTCL-NOS). Prognosis is poor, with a 5-year overall survival of less than 30% (Zain, 2020). Other less common subtypes of TCL include anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma (ATL), angioimmunoblastic TCL, and cutaneous TCL (CTCL) (NCCN, 2020b). The most common CTCL subtype is mycosis fungoides (MF), which is generally indolent; however, because it frequently mimics symptoms associated with other skin conditions, it can be difficult to diagnose in its early stages. Over time, MF can spread across the skin; in advanced stages, it can demonstrate extracutaneous involvement, invading the lymph nodes, blood, or occasionally other organs (NCCN, 2020a). Some patients develop Sézary syndrome, a rare, aggressive form of MF that affects both the skin and peripheral blood. Furthermore, CTCL is often resistant to chemotherapy, and the treatment of patients with advanced disease remains challenging (Alpdogan et al, 2020).


Hematologist/oncologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with T-cell lymphoma (TCL).


Upon completion of this activity, participants should be able to:

Apply guideline recommendations for the differential diagnosis of TCL
Evaluate emerging efficacy and safety data on novel therapies for newly diagnosed and relapsed/refractory TCL
Apply strategies for managing adverse events associated with novel TCL therapies


Mar 17, 2022


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME



Credits / Hours

1.0 CME | 1.0 MOC | 1.0 NCPD | 1.0 ILNA AMA PRA Category 1 Credit



Presenters / Authors / Faculty

Steven M. Horwitz, MD (Chairperson)
Member and Attending Physician
Memorial Sloan Kettering Cancer Center

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from Kyowa Kirin and SeaGen.

Keywords / Search Terms

i3 Health T-Cell Lymphoma, Lymphoma, i3 Health i3 Health, multiple myeloma, MM, online CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME Free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map